行业盛典 再启新程|第七届中国医药创新与投资大会初版日程发布

ZHANG Dan

Vice-Chairman of PhIRDA Drug R&D Specialty Committee, Foreign Academician of Russian Academy of Engineering, Co-founder and Chief Strategy Officer of ClinChoice

Dr. Zhang is a member of grant review committee for National Drug Development Fund of China, and is also a consultant for the National Medical Products Administration (NMPA). He is a member of ICH E19 Expert Working Group. He is also chairing the committee of Pharmaceutical R&D, China Pharmaceutical Industry Research and Development Association. Dr. Zhang is also a senior consultant for the Chinese Academy of Medical Sciences and Peking Union Medical College. He was a member of the Expert Committee on New Drug R&D for the Ministry of Science and Technology of China. Dr. Zhang was the former board of director for the Sino-American Pharmaceutical Association (SAPA) and was the former president of Chinese Biopharmaceutical Association-USA (CBA). Dr. Zhang is chairing the government relationship committee of Bayhelix - an organization hosting senior executives from life science organizations in USA and China. Dr. Zhang received his pre-med training from Peking University and received M.D. from Peking Union Medical College. He then went to the Harvard School of Public Health and received MPH in health policy and management. Then he went to the Wharton Business School of the University of Pennsylvania, where he obtained his master’s degree in healthcare management in 1998.